<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31871">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02023918</url>
  </required_header>
  <id_info>
    <org_study_id>WI178028</org_study_id>
    <nct_id>NCT02023918</nct_id>
  </id_info>
  <brief_title>Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes</brief_title>
  <acronym>PEGIR</acronym>
  <official_title>Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Insulin Resistance But Without Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Francisco General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growth hormone is well known to cause changes in glucose regulation.  People with Laron
      syndrome are born without the growth hormone receptor and are protected from diabetes.  Mice
      who are engineered without the growth hormone receptor are similarly protected from
      diabetes.  Conversely, people who have excessive amounts of growth hormone, such as patients
      with acromegaly, have an increased risk for type 2 diabetes.  In acromegaly patients,
      treatment with pegvisomant, a medication that reduces insulin like growth factor-1 by
      blocking the growth hormone receptor, significantly improves insulin resistance.
      Pegvisomant has not been explored as a possibility for the treatment of type 2 diabetes or
      insulin resistance in people without acromegaly.  In this study, the investigators hope to
      study the metabolic effects of pegvisomant on people who have insulin resistance but not
      diabetes.  Pegivosmant is expected to improve insulin resistance in the liver, fat and
      muscle as well as decrease serum free fatty acids.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigators will measure insulin sensitivity via hyperinsulinemic euglycemic clamp prior to the initiation of the study medication and then again at the end of the 28 days to evaluate the effect of pegvisomant on insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>De novo lipogenesis</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stable isotopes will be measured at fasting and steady state prior to treatment with pegvisomant and then at day 28 after treatment with pegvisomant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipolysis</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Treatment with pegvisomant is expected to alter lipolysis.  To assess this investigators will do fasting and steady state stable isotope measurements prior to treatment with pegvisomant and at day 28 after treatment with pegvisomant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Pegvisomant arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegvisomant</intervention_name>
    <description>Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.</description>
    <arm_group_label>Pegvisomant arm</arm_group_label>
    <other_name>Somavert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18-35

          -  Homeostatic model assessment - insulin resistance (HOMA-IR) &gt;2.77

          -  Able to administer daily subcutaneous injections of pegvisomant

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding in the last 6 months

          -  Liver function tests greater than 3x the upper limits of normal

          -  unstable diet over the last 3 months

          -  unstable weight over the last 6 months

          -  unstable lipid lowering regimen

          -  diabetes - type 1 or type 2

          -  History of major gastrointestinal surgery

          -  History of pancreatic, liver, biliary, or intestinal disease

          -  Fasting blood glucose &gt;126

          -  Fasting triglycerides&gt;300

          -  A1c&gt;6.5
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ethan J Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morris Schambelan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Mulligan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Nordstrom, PhD</last_name>
    <phone>415-476-3090</phone>
    <email>pegirstudy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ada P Lee, MD</last_name>
    <phone>415-476-3090</phone>
    <email>ada.lee@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Nordstrom, PhD</last_name>
      <phone>415-476-3090</phone>
      <email>pegirstudy@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ada P Lee, MD</last_name>
      <phone>415-476-3090</phone>
      <email>ada.lee@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ethan J Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morrie Schambelan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Mulligan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>December 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth hormone antagonism</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
